Nxera Pharma Co., Ltd.
4565.T
Tokyo Stock Exchange896.00
JPY
-59.00
- -
Nxera Pharma Co., Ltd.
4565.T
(Tokyo Stock Exchange)
Recent
price
896.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise engaged in the discovery, development, and commercialization of pharmaceutical innovations across Japan, Switzerland, the United States, Bermuda, and the United Kingdom. The company, formerly known as Sosei Heptares, rebranded to Nxera Pharma in April 2024, signifying its ambition to pioneer the next generation of medical treatments globally. Its commercial portfolio includes PIVLAZ™ (clazosentan) for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage, and QUVIVIQ™ (daridorexant) for addressing insomnia, which launched in Japan in late 2024. The revenue model combines product sales, particularly within Japan and the broader APAC region, with significant milestone and royalty payments from its numerous alliances with major global pharmaceutical firms. Nxera Pharma maintains a robust pipeline, encompassing over 30 programs from early discovery through late-stage clinical trials, driven by its proprietary NxWave™ platform focusing on G Protein-Coupled Receptors (GPCRs) for structure-based drug design. A recent strategic pivot in November 2025 has directed approximately 80% of its pipeline investment towards obesity and metabolic disorders, an area of significant unmet need, while non-priority assets are being evaluated for partnerships or discontinuation. The newly unveiled proprietary pipeline in this domain features an oral small molecule GLP-1 agonist alongside six additional programs targeting GIP, Amylin, and Apelin receptors, designed to address long-term weight management and associated metabolic conditions. Key development candidates also include NBI-'568, a muscarinic agonist, currently in Phase 3 trials through a collaboration with Neurocrine Biosciences, and HTL0039732, an immuno-oncology agent, which has entered Phase 2a clinical studies and demonstrated encouraging early efficacy in Phase 1. The company fosters extensive strategic collaborations, including multi-target discovery agreements with AbbVie for neurological diseases, having recently achieved multiple R&D milestones, and with Eli Lilly for diabetes and metabolic disorders. Further partnerships involve PrecisionLife for target identification in autoimmune disorders, Antiverse for AI-driven antibody therapeutics, and Viatris for cenerimod commercialization in Japan and APAC. Nxera Pharma Co., Ltd. was established in 1990 and operates from its headquarters in Tokyo, Japan.